Recent FDA warning letters indicate that many drug manufacturers do not have their manufacturing in a state of current good manufacturing practices (CGMPs) control. During the first half of 2017, the FDA cited adulterated products and insanitary conditions as the two most common violations in drug manufacturing. Here are four ways an automated quality and compliance management system builds control into the production process with respect to adulteration and potential contamination.

 …